Recent patents on endocrine, metabolic & immune drug discovery最新文献

{"title":"Cytology for the detection of early recurrence of gynecologic cancer in the vaginal vault.","authors":"Lucia A S Lara,&nbsp;Jurandyr M de Andrade,&nbsp;Francisco J C Dos Reis","doi":"10.2174/1872214808666140715092054","DOIUrl":"https://doi.org/10.2174/1872214808666140715092054","url":null,"abstract":"<p><strong>Objective: </strong>The real benefit of follow-up cervical cytology in women treated for gynecological cancer is unclear. This study was designed to assess the rate of success of cytological examinations in the detection of early vaginal recurrence of gynecological cancer in women found by other methods to have vaginal recurrence of cervical and endometrial cancer.</p><p><strong>Data sources: </strong>Records of cytological examinations.</p><p><strong>Study selection: </strong>Thirty-three women treated for early and invasive cervical and endometrial cancer with recurrence in the vaginal vault were retrospectively analyzed.</p><p><strong>Data extraction: </strong>Records from 1979 to 2010.</p><p><strong>Data synthesis: </strong>Sixteen women (48.5%) had symptomatic vaginal recurrence associated with distant metastases, whereas 17 (51.5%) had vaginal recurrence only. Cytology was negative in 12 women (36.4%) with both symptomatic and asymptomatic recurrence and positive in the other 21 (63.6%). In 9 of these 21 women (42.9%), the disease was limited to the vaginal vault, whereas the remaining 12 (57.1%) presented with vaginal lesions associated with distant metastases. Cytology was positive in 9 of the 17 (52.9%) women whose recurrence was limited to the vaginal vault and negative in 8 (47.1%).</p><p><strong>Conclusion: </strong>Vaginal cytology yielded false-negative results in almost half of the women with vaginal recurrence of gynecological cancer. Patents of methods used for early diagnosis and detection of immortalization of cervical cancer are also reviewed in this article.</p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 2","pages":"135-9"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32503729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provision.","authors":"Mark A Babizhayev,&nbsp;Anne Kasus-Jacobi,&nbsp;Khava S Vishnyakova,&nbsp;Yegor E Yegorov","doi":"10.2174/1872214808666140608145810","DOIUrl":"https://doi.org/10.2174/1872214808666140608145810","url":null,"abstract":"<p><p>Telomere length is emerging as a biomarker for aging and survival is paternally inherited and associated with parental lifespan. Telomere-associated cellular senescence may contribute to certain age-related disorders, including an increase in cancer incidence, wrinkling and diminished skin elasticity, atherosclerosis, osteoporosis, weight loss, age-related cataract, glaucoma and others. Shorter telomere length in leukocytes was associated cross-sectionally with cardiovascular disorders and its risk factors, including pulse pressure and vascular aging, obesity, vascular dementia, diabetes, coronary artery disease, myocardial infarction (although not in all studies), cellular turnover and exposure to oxidative and inflammatory damage in chronic obstructive pulmonary disease. Effective regulation of abnormal therapeutic targets of an age-related disease requires the alteration of either the topological structure or dynamic characteristics of telomeres which are DNA-protein structures at the ends of eukaryotic chromosomes, the DNA of which comprise noncoding repeats of guanine-rich sequences. Telomeric DNA plays a fundamental role in protecting the cell from recombination and degradation, including those as the metabolic super-achievers in the body, organ systems in a given target network of a disease and aging. In order to manage and control the complex direct and indirect target hubs, in this paper, a review of the recent patents is made analyzing techniques, new approaches developed during the last years in adaptive pharmacology directed at slowing and preventing the loss of telomere length that may slow aging using pharmaceutical and nutritional module-based designs, such as with regard to the timing of administration of imidazole-containing dipeptides. We discuss our recent identification of the role of neuron-specific imidazole- containing dipeptide based compounds (L-carnosine, N-acetylcarnosine, carcinine) that regulate and therapeutically control telomere shortening, telomerase activity and cellular senescence. We support a therapeutic concept of using nonhydrolyzed forms of naturally occurring imidazole-dipeptide based compounds carnosine and carcinine, making it clinically possible that slowing down the rate of telomere shortening could slow down the human aging process in specific tissues where proliferative senescence is known to occur with the demonstrated evidence of telomere shortening appeared to be a hallmark of oxidative stress and disease. The preliminary longitudinal studies of elderly individuals suggest that longer telomeres are associated with better survival and an advanced oral pharmaconutrition provision with non-hydrolyzed carnosine (or carcinine and patented compositions thereof) is a useful therapeutic tool of a critical telomere length maintenance (allowing indirectly to manipulate with telomerase activity) that may fundamentally be applied in the therapeutic treatment of agerelated sight-threatening eye disorders","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 3","pages":"153-79"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32406906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome and asthma.","authors":"Jenny V Garmendia,&nbsp;Dolores Moreno,&nbsp;Alexis H Garcia,&nbsp;Juan B De Sanctis","doi":"10.2174/1872214807666140107151023","DOIUrl":"https://doi.org/10.2174/1872214807666140107151023","url":null,"abstract":"<p><p>Metabolic syndrome (MetS) is a syndrome that involves at least three disorders dyslipidemia, insulin resistance, obesity and/or hypertension. MetS has been associated with several chronic diseases in the adulthood; however, in the recent years, the syndrome was redefined in children. Girls with early menarche and asthma, and children with MetS and asthma that reach adulthood appear to have higher risk to develop severe or difficult to control asthma and a higher probability to suffer cardiovascular diseases. It has been proposed that patients with MetS and endocrinological disorders should be considered a different entity in which pharmacologic treatment should be adjusted according to the individual. Recent patents on the field have addressed new issues on how endocrine control should be managed along with asthma therapeutics. In the near future, new approaches should decrease the high morbidity and mortality associated to these types of patients. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"60-6"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214807666140107151023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32007588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Euthyroid depression: the role of thyroid hormone.","authors":"Sanjay Kalra,&nbsp;Yatan Pal Singh Balhara","doi":"10.2174/1872214807666131229130540","DOIUrl":"https://doi.org/10.2174/1872214807666131229130540","url":null,"abstract":"Thyroid dysfunction and psychiatric disorders share a bidirectional relation. Thyroid hormones have been found to affect the central nervous system both structurally and functionally. Conventional antidepressant drug therapy is characterized by a delayed and at times suboptimal response. Various strategies have been devised in order to circumvent this limitation. L- Thyroxine has been used as both acceleration therapy and augmentation therapy as adjuvant therapy with antidepressants. The hormone has also been used as monotherapy, both in prevention and management of depression. The potential use of thyroid hormone as an adjunct therapy in management of euthyroid depression and relevant patents has been discussed.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"38-41"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214807666131229130540","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31984718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity.","authors":"Poupak Fallahi,&nbsp;Silvia Martina Ferrari,&nbsp;Alda Corrado,&nbsp;Dilia Giuggioli,&nbsp;Clodoveo Ferri,&nbsp;Alessandro Antonelli","doi":"10.2174/1872214808666140623114315","DOIUrl":"https://doi.org/10.2174/1872214808666140623114315","url":null,"abstract":"<p><p>The C-X-C chemokine receptor (CXCR)3 and its chemokines (CXCL9, CXCL10, CXCL11) are involved in the pathogenesis of autoimmune thyroiditis (AT), Graves' disease (GD) and Graves' Ophthalmopathy (GO). Under the influence of interferon(IFN)γ, the IFNγ-induced protein 10 (IP-10/CXCL10) is secreted by thyrocytes, orbital fibroblasts and preadipocytes. In tissue, Th1 lymphocytes are recruited; hence IFNγ is enhanced, which stimulates CXCL10 secretion reiterating the autoimmune process. The presence of elevated levels of CXCL10 in peripheral liquids is considered a marker of Th1 orientated immune response. High levels of circulating CXCL10 (sCXCL10) have been shown in patients with AT, overall with hypothyroidism. In GD and GO patients high sCXCL10 have been shown particularly in the active disease. A modulatory role of peroxisome proliferator-activated receptor (PPAR)γ or - α agonists on CXCR3 chemokines in AT, GD and GO and the immuno-modulatory effect of methimazole on CXCR3 chemokines in GD have been shown. Further studies are ongoing to explore the use of new molecules that act as antagonists of CXCR3, or block CXCL10, in autoimmune disorders, and many interesting patents have been recently applied. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 2","pages":"95-101"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32446359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative models for the empowerment of patients with type 2 diabetes: the CAIPaDi program.","authors":"S. Hernández-Jiménez, Cristina García-Ulloa, R. Mehta, C. Aguilar-Salinas, D. Kershenobich-Stalnikowitz","doi":"10.2174/1872214808666141110160147","DOIUrl":"https://doi.org/10.2174/1872214808666141110160147","url":null,"abstract":"Empowerment interventions for chronic diseases are an evolving process. No agreement exists regarding the necessary components and methodologies to be applied. Systematic reviews have assessed the effect of self-management interventions. Improvements in illness beliefs, adherence to drug therapy and glucose monitoring have been reported. In the long term, no major changes have been achieved in weight, physical activity, smoking status, and depression scores. There is a need for additional studies. The CAIPaDi (Centro de Atención Integral del Paciente con Diabetes) program is an intervention designed to provide education and empowerment techniques (using simple low-cost interactive tools) over a short period of time followed by at-distance support using internet or cell phone technology. The target population consists of patients with type 2 diabetes, free of chronic complications who are non-smokers. The intervention is composed of four monthly visits followed by a continuous at-distance support system. At each visit, patients stay for six hours in the center. Information is presented in group sessions. Empowerment techniques are applied during individual exchanges with the team or during facilitated group sessions. In summary, empowerment programs are an unmet need in many healthcare services. This review also discusses relevant studies and patents in the management of type 2 diabetes.","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"9 1","pages":"202-9"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90397033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dendritic cell vaccine and cancer treatment: new patents.","authors":"André A R Aleixo,&nbsp;Márcia A Michelin,&nbsp;Eddie F C Murta","doi":"10.2174/1872214807666140107152008","DOIUrl":"https://doi.org/10.2174/1872214807666140107152008","url":null,"abstract":"<p><p>Dendritic cell (DC) immunotherapy has been used to treat various types of tumors. Although it is already in use in clinical practice, the mechanisms through which it acts need clarification. In addition, the processes used to obtain DCs need to be improved so that more effective treatments can be offered. In this article, we present an update on the application of DC immunotherapy and the patents involved in the process. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"26-9"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214807666140107152008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32007589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of lysosomal storage diseases: recent patents and future strategies.","authors":"Saida Ortolano,&nbsp;Irene Viéitez,&nbsp;Carmen Navarro,&nbsp;Carlos Spuch","doi":"10.2174/1872214808666140115111350","DOIUrl":"https://doi.org/10.2174/1872214808666140115111350","url":null,"abstract":"<p><p>Lysosomal storage diseases (LSDs) are a group of rare genetic multisystemic disorders, resulting in deficient lysosomal activity. These pathologies are characterized by progressive accumulation of storage material within the lysosomes, ultimately leading to organ dysfunctions. LSDs patient's clinical outcomes have significantly improved, since the advent of enzyme replacement therapy (ERT). ERT is approved worldwide for 6 LSDs: Gaucher disease, Fabry disease, Mucopolysaccharidosis types I, II, and VI, and Pompe disease. The efficacy and safety of ERT for LSDs has been confirmed by extensive clinical trials, however therapy with infused protein is life-long and disease progression is still observed in treated patients. Obstacles to successful ERT, such as immune reactions against the infused enzyme, miss-targeting of recombinant enzymes, and difficult delivery to crucial tissues (i.e. brain and bone), determine the need for further research, in order to ameliorate therapeutic strategies. Viral gene therapy, stem cell based therapy, pharmacological chaperones and could be considered essential tools for future improvement of recombinant enzyme trafficking and targeting. This review will discuss recent patents and new strategic approaches for enzyme delivery to highlight the most relevant aspects, concerning next generation LSDs treatment. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"9-25"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214808666140115111350","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32037136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin therapy: going the \"smarter\" way.","authors":"Sanjay Kalra,&nbsp;Ameya Joshi,&nbsp;Girish Parmar","doi":"10.2174/1872214808666140627105457","DOIUrl":"https://doi.org/10.2174/1872214808666140627105457","url":null,"abstract":"<p><p>Insulin pharmacology has evolved from nonhuman source based extraction of insulin, to use of recombinant technologies for human insulin production, to tailor made synthetic insulin analogues. The delivery techniques of insulin have also improved, from injections to pumps, and to pumps with sensors. However, to achieve the final goal of a closed loop insulin delivery is far from achieved. One of the researches in this direction includes synthetic smart insulins. These are systems with chemical sensors for glucose, linked to reactions that trigger glucose mediated insulin delivery. Interest in this field is high and recent publications and patents show promise. The current review tries to summarize the basic concept of smart insulin as well as cater the recent developments and patents in this direction. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 2","pages":"79-84"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32463288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of antioxidant extract from cherries on diabetes.","authors":"Tahsini Lachin","doi":"10.2174/1872214808666140121151334","DOIUrl":"https://doi.org/10.2174/1872214808666140121151334","url":null,"abstract":"<p><p>Diabetes is a chronic metabolic disorder in humans constituting a major health concern today whose prevalence has continuously increased worldwide over the past few decades. Production of reactive oxygen species (ROS) and disturbed capacity of antioxidant defense in diabetic subjects have been reported. It has been suggested that enhanced production of free radicals and oxidative stress is the central event for the development of diabetic complications. Antioxidants can play an important role in the improvement of diabetes. There are many reports on the effects of antioxidants in the management of diabetes. This study aimed at evaluating the effect of antioxidant extract and purified sweet and sour Cherries on hyperglycemia, microalbumin and creatinine level in alloxan-induced diabetic rats. Thirty six adult Male Wistar rats were divided equally into six groups. Diabetes was induced in the rats by an intraperitoneal injection with 120 mg/kg body weight of alloxan. Oral administration of cherry extract at a concentration of 200 mg/kg body weight for 30 days significantly reduced the levels of blood glucose, and urinary microalbumin. Also an increase in the creatinine secretion level in urine was observed in the diabetic rats treated with the cherry extract as compared to untreated diabetic rats. In this paper, the most recent patent on the identification and treatment of diabetes is used. In conclusion, cherry antioxidant extract proved to have a beneficial effect on the diabetic rats in this study. In light of these advantageous results, it is advisable to broaden the scale of use of sweet and sour cherries extract in a trial to alleviate the adverse effects of diabetes. </p>","PeriodicalId":89474,"journal":{"name":"Recent patents on endocrine, metabolic & immune drug discovery","volume":"8 1","pages":"67-74"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1872214808666140121151334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32046821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}